NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $46.09 -0.78 (-1.66 %) (As of 02/17/2020 02:45 AM ET) Add Compare Today's Range$45.74Now: $46.09▼$47.2950-Day Range$39.34MA: $42.55▼$46.8752-Week Range$21.56Now: $46.09▼$53.70Volume1.14 million shsAverage Volume1.10 million shsMarket Capitalization$7.10 billionP/E RatioN/ADividend YieldN/ABeta2.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:ACAD Previous Symbol CUSIPN/A CIK1070494 WebN/A PhoneN/ADebt Debt-to-Equity Ratio0.01 Current Ratio10.96 Quick Ratio10.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$223.81 million Price / Sales31.72 Cash FlowN/A Price / Cash FlowN/A Book Value$3.83 per share Price / Book12.03Profitability EPS (Most Recent Fiscal Year)($1.94) Net Income$-245,190,000.00 Net Margins-82.48% Return on Equity-50.15% Return on Assets-43.69%Miscellaneous Employees465 Outstanding Shares154,020,000Market Cap$7.10 billion Next Earnings Date2/26/2020 (Confirmed) OptionableOptionable Receive ACAD News and Ratings via Email Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ACAD Rates by TradingView ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) released its quarterly earnings data on Wednesday, October, 30th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.40) by $0.11. The biopharmaceutical company earned $94.59 million during the quarter, compared to analysts' expectations of $88.49 million. ACADIA Pharmaceuticals had a negative net margin of 82.48% and a negative return on equity of 50.15%. The firm's quarterly revenue was up 62.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.50) EPS. View ACADIA Pharmaceuticals' Earnings History. When is ACADIA Pharmaceuticals' next earnings date? ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for ACADIA Pharmaceuticals. How can I listen to ACADIA Pharmaceuticals' earnings call? ACADIA Pharmaceuticals will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What price target have analysts set for ACAD? 15 equities research analysts have issued 12-month price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $31.00 to $70.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $52.60 in the next year. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals. What is the consensus analysts' recommendation for ACADIA Pharmaceuticals? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings, 12 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals. What are Wall Street analysts saying about ACADIA Pharmaceuticals stock? Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock: 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (12/31/2019) 2. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $71.86/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $3.50 discounted back to and (b) an NPV of $47.36/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (5/3/2019) 3. JPMorgan Chase & Co. analysts commented, "Dexcom posted another sizable sales beat, besting consensus expectation by almost $35M, and raised 2019 revenue guidance by $75M. The familiar topics of pricing and competition ruled much of the discussion, but there was little new on either front, in our view. Some revenue is expected to go toward higher operating expenses as the company invests in new markets, the Verily product, and G6 line extensions. We remain concerned that pricing pressures could arise—perhaps suddenly—but also may not occur for years. We frankly haven’t figured out what work to do to predict when or if insurers may push on price due to competition pricing lower. We remain Neutral as we feel we have no way to eliminate or estimate this risk but do believe DXCM shares will move higher should pricing fears not play out. CGM is good medicine and should be used by all MDI diabetics, in our view." (5/2/2019) Has ACADIA Pharmaceuticals been receiving favorable news coverage? Media headlines about ACAD stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for ACADIA Pharmaceuticals. Who are some of ACADIA Pharmaceuticals' key competitors? Some companies that are related to ACADIA Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), The Medicines (MDCO), Amarin (AMRN), Ascendis Pharma A/S (ASND), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Axsome Therapeutics (AXSM), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Synthorx (THOR), Aurinia Pharmaceuticals (AUPH), Cambrex (CBM), Arvinas (ARVN) and Alder Biopharmaceuticals (ALDR). What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), Sarepta Therapeutics (SRPT), Celgene (CELG), NVIDIA (NVDA), Netflix (NFLX), Synergy Pharmaceuticals (SGYP), Alibaba Group (BABA), Gilead Sciences (GILD), Citigroup (C) and Tesla (TSLA). Who are ACADIA Pharmaceuticals' key executives? ACADIA Pharmaceuticals' management team includes the folowing people: Mr. Stephen R. Davis, CEO & Director (Age 58)Dr. Srdjan R. Stankovic, Pres (Age 62)Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40) Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (13.56%), State Street Corp (2.60%), First Trust Advisors LP (0.93%), Artisan Partners Limited Partnership (0.85%), Goldman Sachs Group Inc. (0.81%) and Pictet Asset Management Ltd. (0.78%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Institutional Ownership Trends for ACADIA Pharmaceuticals. Which major investors are selling ACADIA Pharmaceuticals stock? ACAD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, Bank of America Corp DE, Artisan Partners Limited Partnership, PNC Financial Services Group Inc., Franklin Resources Inc., Cubist Systematic Strategies LLC and Credit Suisse AG. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Elena Ridloff, Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Insider Buying and Selling for ACADIA Pharmaceuticals. Which major investors are buying ACADIA Pharmaceuticals stock? ACAD stock was acquired by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Point72 Asset Management L.P., Renaissance Technologies LLC, State Street Corp, Fairmount Funds Management LLC, Pictet Asset Management Ltd., Lord Abbett & CO. LLC and Jennison Associates LLC. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $46.09. How big of a company is ACADIA Pharmaceuticals? ACADIA Pharmaceuticals has a market capitalization of $7.10 billion and generates $223.81 million in revenue each year. The biopharmaceutical company earns $-245,190,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.View Additional Information About ACADIA Pharmaceuticals. MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 727 (Vote Outperform)Underperform Votes: 393 (Vote Underperform)Total Votes: 1,120MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2020 by MarketBeat.com StaffFeatured Article: What is a back-end load?
